Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ATX-295 |
| Synonyms | |
| Therapy Description |
ATX-295 inhibits KIF18A, which potentially results in decreased tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 3784). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ATX-295 | ATX295|ATX 295 | ATX-295 inhibits KIF18A, which potentially results in decreased tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 3784). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06799065 | Phase I | ATX-295 | First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer | Recruiting | USA | 0 |